1. Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. WIREs Dev Biol. 2015; 4(3): 215-266. doi: 10.1002/ wdev.176
2. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000; 277(2): 494-498. doi: 10.1006/bbrc.2000.3696
3. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nat Genet. 2000; 26(3): 345-348. doi: 10.1038/81664
4. Liu S, Guo R, Simpson LG, Xiao Z-S, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003; 278(39): 37419- 37426. doi: 10.1074/jbc.M304544200
5. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD. Pathogenic role of FGF-23 in Dmp1-null mice. Am J Physiol Endocrinol Metab. 2008; 295(2): E254-E261. doi: 10.1152/ ajpendo.90201.2008
6. Masuda Y, Ohta H, Morita Y, et al. Expression of FGF-23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol Pharm Bull. 2015; 38(5): 687- 693. doi: 10.1248/bpb.b14-00276
7. Liu S, Quarles LD. How fibroblast growth factor 23 works. J of the Am Soc of Nephrology. 2007; 18(6): 1637-1647. doi: 10.1681/ASN.2007010068
8. Bowman MH, Gardner B, Earley J, Rateri D, Daugherty A, Yan L. Abstract 478: FGF-23 expression in cardiac fibroblasts is augmented by S100/Calgranulins-Mediated Inflammation and Associated With Cardiac Hypertrophy, but Not in Angiotensin II-Induced Cardiac Hypertrophy. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015; 35(Suppl 1):A478. Website. http:// atvb.ahajournals.org/content/35/Suppl_1/A478.abstract. Accessed March 9, 2016.
9. Nabeshima Y, Imura H. alpha-Klotho: a regulator that integrates calcium homeostasis. Am J Nephrol. 2008; 28(3): 455- 464. doi: 10.1159/000112824
10. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013; 75(1): 503-533. doi: 10.1146/annurev-physiol-030212-183727
11.Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281(10): 6120-6123. doi: 10.1074/jbc.C500457200
12. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118(12): 3820-3828. doi: 10.1172/JCI36479
13. Nabeshima Y. The discovery of alpha-Klotho and FGF-23 unveiled new insight into calcium and phosphate homeostasis. Cell Mol Life Sci. 2008; 65(20): 3218-3230. doi: 10.1007/ s00018-008-8177-0
14. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281(23): 15694-15700. doi: 10.1074/jbc.M601252200
15. U.S. National Library of Medicine. Genetics Home Reference: FGFR1 2015 [cited 2015 17 November]. Available from: http://ghr.nlm.nih.gov/gene/FGFR1. Accessed March 9, 2016.
16. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem. 1997; 45(7): 1005-1019. doi: 10.1177/002215549704500710
17. The Human Protein Atlas. FGFR1 [cited 2015 18 November]. Available from: http://www.proteinatlas.org/ENSG00000077782-FGFR1/tissue. Accessed March 9, 2016.
18. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer. 1992; 66(2): 273-280. doi: 10.1177/002215549704500710
19. The Human Protein Atlas. FGFR3 [cited 2015 18 November]. Website. http://www.proteinatlas.org/ENSG00000068078- FGFR3/tissue. Accessed March 9, 2016.
20. The Human Protein Atlas. FGFR4 [cited 2015 18 November]. Available from: http://www.proteinatlas.org/ENSG00000160867-FGFR4/tissue. Accessed March 9, 2016.
21. Taylor KR, Rudisill JA, Gallo RL. Structural and sequence motifs in dermatan sulfate for promoting fibroblast growth factor-2 (FGF-2) and FGF-7 activity. J Biol Chem. 2005; 280(7): 5300-5306. doi: 10.1074/jbc.M410412200
22. Beer HD, Vindevoghel L, Gait MJ, et al. Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000; 275(21): 16091-16097. doi: 10.1074/jbc.275.21.16091
23. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD. FGFR3 and FGFR4 do not mediate renal effects of FGF-23. J Am Soc Nephrol. 2008; 19(12): 2342-2350. doi: 10.1681/ASN.2007121301
24. Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J. fgfr1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev. 1994; 8(24): 3032-3044. doi: 10.1101/gad.8.24.3032
25. Wohrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011; 26(10): 2486-2497. doi: 10.1002/jbmr.478
26. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004; 314(2): 409-414. doi: 10.1016/j. bbrc.2003.12.102
27. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 2005; 68(3): 1148-1153. doi: 10.1111/j.1523- 1755.2005.00506.x
28. Andrukhova O, Smorodchenko A, Egerbacher M, et al. FGF-23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 2014; 33(3): 229-246. doi: 10.1002/ embj.201284188
29. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006; 17(5): 1305-1315. doi: 10.1681/ ASN.2005111185
30. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429-435. doi: 10.1359/ JBMR.0301264
31. Marsell R, Krajisnik T, Goransson H, et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant. 2008 ;23(3): 827- 833 doi: 10.1093/ndt/gfm672
32. Ozeki M, Fujita S, Kizawa S, et al. Association of serum levels of FGF-23 and alpha-Klotho with glomerular filtration rate and proteinuria among cardiac patients. BMC Nephrol. 2014; 15: 147. doi: 10.1186/1471-2369-15-147
33. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003; 278(4): 2206-2211. doi: 10.1074/ jbc.M207872200
34. Valdivielso JM, Cannata-Andia J, Coll B, Fernandez E. A new role for vitamin D receptor activation in chronic kidney disease. Am J Physiol Renal Physiol. 2009; 297(6): F1502-F1509. doi: 10.1152/ajprenal.00130.2009
35. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct. 2004; 29(4): 91-99. doi: 10.1247/csf.29.91
36. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, NavehMany T. PTH increases FGF-23 gene expression and mediates the high-FGF-23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010; 299(4): F882-F889. doi: 10.1152/ajprenal.00360.2010
37. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF-23 in rats. J Clin Invest. 2007; 117(12): 4003-4008. doi: 10.1172/JCI32409
38. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51. doi: 10.1038/36285
39. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008; 23(6): 939-948. doi: 10.1359/jbmr.080220
40. White KE, Cabral JM, Davis SI, et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet. 2005; 76(2): 361-367. doi: 10.1086/427956
41. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF-23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98(11): 6500-6505. doi: 10.1073/pnas.101545198
42. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF-23. Nature. 2006; 444(7120): 770-7744. doi: 10.1038/nature05315
43. Jimbo R, Shimosawa T. Cardiovascular risk factors and chronic kidney disease-FGF-23: A key molecule in the cardiovascular disease. Int J Hypertens. 2014; 2014: 381082. doi: 10.1155/2014/381082
44. Falcini F, Rigante D, Masi L, et al. Fibroblast growth factor 23 (FGF-23) gene polymorphism in children with kawasaki syndrome (KS) and susceptibility to cardiac abnormalities. Ital J Pediatr. 2013; 39: 69. doi: 10.1186/1824-7288-39-69
45. di Giuseppe R, Buijsse B, Hirche F, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2014; 99(3): 947-955. doi: 10.1210/jc.2013- 2963
46. Hu MC, Kuro-o M, Moe OW. Secreted klotho and chronic kidney disease. Adv Exp Med Biol. 2012; 728: 126-157. doi: 10.1007/978-1-4614-0887-1_9
47. Lysaght AC, Yuan Q, Fan Y, et al. FGF-23 deficiency leads to mixed hearing loss and middle ear malformation in mice. PLoS One. 2014; 9(9): e107681. doi: 10.1371/journal.pone.0107681
48. Feng S, Wang J, Zhang Y, Creighton CJ, Ittmann M. FGF-23 promotes prostate cancer progression. Oncotarget. 2015; 6(19): 17291-17301. doi: 10.18632/oncotarget.4174
49. Kim HJ, Kim KH, Lee J, et al. Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF-23, are associated with prostate cancer risk. BJU Int. 2014; 114(2): 303-310. doi: 10.1111/bju.12396
50. Wright CB, Dong C, Stark M, et al. Plasma FGF-23 and the risk of stroke: The northern manhattan study (NOMAS). Neurology. 2014; 82(19): 1700-1706. doi: 10.1212/ WNL.0000000000000410
51. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18(7): 2116-2124. doi: 10.1681/ASN.2006121385
52. Jimbo R, Kawakami-Mori F, Mu S, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 2014; 85(5): 1103- 1111. doi: 10.1038/ki.2013.332
53. Lindberg K, Olauson H, Amin R, et al. Arterial klotho expression and FGF-23 effects on vascular calcification and function. PLoS One. 2013; 8(4): e60658. doi: 10.1371/journal. pone.0060658
54. Dai B, David V, Martin A, et al. A comparative transcriptome analysis identifying FGF-23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012; 7(9): e44161. doi: 10.1371/journal.pone.0044161
55. Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol. 2003; 10(2): 184-196. doi: 10.1067/mnc.2003.392
56. Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015; 22(6): 1020-1032. doi: 10.1016/j.cmet.2015.09.002
57. Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben R. FGF-23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone. 2012; 51(3): 621-628. doi: 10.1016/j. bone.2012.05.015
58. Sitara D, Kim S, Razzaque MS, et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008; 4(8): e1000154. doi: 10.1371/journal. pgen.1000154
59. Sitara D, Razzaque MS, St-Arnaud R, et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol. 2006; 169(6): 2161-2170. doi: 10.2353/ajpath.2006.060329
60. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phos phate wasting disorders. Endocrinology. 2004; 145(11): 5269- 5279. doi: 10.1210/en.2004-0233
61. Isakova T, Wolf MS. FGF-23 or PTH: which comes first in CKD? Kidney Int. 2010; 78(10): 947-949. doi: 10.1038/ ki.2010.281
62. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12): 1370-1378. doi: 10.1038/ki.2011.47
63. Evenepoel P, Meijers B, Viaene L, et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010; 5(7): 1268-1276. doi: 10.2215/CJN.08241109
64. Almaden Y, Canalejo A, Hernandez A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996; 11(7): 970-976. doi: 10.1002/jbmr.5650110714
65. Faul C, Amaral AP, Oskouei B, et al. FGF-23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11): 4393- 4408. doi: 10.1172/JCI46122